Roles of the immune system in skin cancer

British Journal of Dermatology

Volumn 165, Issue 5, 2011, Pages 953-965

  Rangwala, S ^a   Tsai, K Y ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALBINTERFERON ALPHA2B; ALEFACEPT; AZATHIOPRINE; CANCER VACCINE; CORTICOSTEROID; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETANERCEPT; EVEROLIMUS; GAMMA INTERFERON; GOLIMUMAB; GP100 VACCINE; IMIQUIMOD; INFLIXIMAB; INTERLEUKIN 10; IPILIMUMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN P53; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RETINOBLASTOMA PROTEIN; STAT1 PROTEIN; STEROID; TACROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; USTEKINUMAB; IMMUNOSUPPRESSIVE AGENT;

BASAL CELL CARCINOMA; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; DISEASE COURSE; DISEASE FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY TRANSPLANTATION; LYMPHATIC LEUKEMIA; MELANOMA; MERKEL CELL TUMOR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SEROTYPE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH; ULTRAVIOLET RADIATION; WART VIRUS; WOUND HEALING; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE SUBPOPULATION; METHODOLOGY; RISK FACTOR; SKIN TUMOR; VIRUS INFECTION;

HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE SUBSETS; RISK FACTORS; SKIN NEOPLASMS; ULTRAVIOLET RAYS; VIRUS DISEASES; WOUND HEALING;

EID: 84856375893     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10507.x     Document Type: Review

References (248)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Rogers HW, Weinstock MA, Harris AR et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283-7.
3. The Lewin Group. The Burden of Skin Diseases 2005. Cleveland, OH and Washington, DC: The Society for Investigative Dermatology and The American Academy of Dermatology Association, 2005.
4. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006; 90:1-50. (Pubitemid 43765795)
5. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991; 262:3-11.
6. Starnes CO. Coley's toxins in perspective. Nature 1992; 357:11-12.
7. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med 1982; 55:329-33. (Pubitemid 13119667)
8. Schreiber RD, Old LJ, Smyth MJ. Cancer Immmunoediting: integrating immunity's roles in cancer-suppression and promotion. Science 2011; 331:1565-70.
9. Shankaran V, Ikeda H, Bruce AT et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410:1107-11. (Pubitemid 32391043)
10. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immu-nocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61. (Pubitemid 28293291)
11. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37.
12. Dunn GP, Bruce AT, Ikeda H et al. Cancer immunoediting: from im-munosurveillance to tumor escape. Nat Immunol 2002; 3:991-8. (Pubitemid 35363648)
13. Koebel CM, Vermi W, Swann JB et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450:903-7. (Pubitemid 350231320)
14. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat Immunol 2002; 3:999-1005. (Pubitemid 35363649)
15. Paulson KG, Iyer JG, Tegeder AR et al. Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011; 29:1539-46.
16. Clemente CG, Mihm MC Jr, Bufalino R et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77:1303-10. (Pubitemid 26102328)
17. Rao UN, Lee SJ, Luo W et al. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (T4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol 2010; 133:646-53.
18. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000; 23:101-13.
19. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348:1681-91. (Pubitemid 36459475)
20. Bouwes Bavinck JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow-up study. Transplantation 1996; 61:715-21. (Pubitemid 26097231)
21. Ramsay HM, Fryer AA, Hawley CM et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147:950-6. (Pubitemid 35365443)
22. Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47:1-17.
23. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60:183-9.
24. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49:506-9. (Pubitemid 20110465)
25. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40:177-86. (Pubitemid 29072794)
26. Lindelof B, Sigurgeirsson B, Gabel H et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000; 143:513-19.
27. Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer 1999; 85:1758-64. (Pubitemid 29169677)
28. Euvrard S, Kanitakis J, Pouteil-Noble C et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995; 27:1767-8.
29. Lott DG, Manz R, Koch C et al. Aggressive behavior of nonmelanotic skin cancers in solid organ transplant recipients. Transplantation 2010; 90:683-7.
30. Carucci JA, Martinez JC, Zeitouni NC et al. In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients. Dermatol Surg 2004; 30:651-5. (Pubitemid 38525896)
31. Martinez JC, Otley CC, Stasko T et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: a multi-center collaborative study. Arch Dermatol 2003; 139:301-6. (Pubitemid 36330577)
32. Wells JL, Shirai K. Systemic therapy for squamous cell carcinoma of the skin in organ transplant recipients. Am J Clin Oncol 2011 Feb 3. [Epub ahead of print].
33. Dantal J, Hourmant M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351:623-8. (Pubitemid 28098444)
34. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998; 65:1270-2. (Pubitemid 28224350)
35. Otley CC, Maragh SL. Reduction of immunosuppression for transplant-associated skin cancer: rationale and evidence of efficacy. Dermatol Surg 2005; 31:163-8. (Pubitemid 40990944)
36. Davis MD, Perniciaro C, Dahl PR et al. Exaggerated arthropod-bite lesions in patients with chronic lymphocytic leukemia: a clinical, histopathologic, and immunopathologic study of eight patients. J Am Acad Dermatol 1998; 39:27-35. (Pubitemid 28332304)
37. Adami J, Frisch M, Yuen J et al. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. BMJ 1995; 310:1491-5.
38. Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975; 232:267-9.
39. Mehrany K, Weenig RH, Pittelkow MR et al. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatol Surg 2005; 31:38-42. (Pubitemid 40094060)
40. Mehrany K, Weenig RH, Pittelkow MR et al. High recurrence rates of basal cell carcinoma after Mohs surgery in patients with chronic lymphocytic leukemia. Arch Dermatol 2004; 140:985-8. (Pubitemid 39062650)
41. Mehrany K, Weenig RH, Lee KK et al. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol 2005; 53:1067-71. (Pubitemid 41677335)
42. Smoller BR, Warnke RA. Cutaneous infiltrate of chronic lympho-cytic leukemia and relationship to primary cutaneous epithelial neoplasms. J Cutan Pathol 1998; 25:160-4. (Pubitemid 28130162)
43. Dargent JL, Kornreich A, Andre L et al. Cutaneous infiltrate of chronic lymphocytic leukemia surrounding a primary squamous cell carcinoma of the skin. Report of an additional case and reflection on its pathogenesis. J Cutan Pathol 1998; 25:479-80. (Pubitemid 28474808)
44. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336:897-904. (Pubitemid 27137189)
45. Leisenring W, Friedman DL, Flowers MED et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24:1119-26. (Pubitemid 46638809)
46. Hasegawa W, Pond GR, Rifkind JT et al. Long-term follow-up of secondary malignancies in adults after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 35:51-5.
47. Lishner M, Patterson B, Kandel R et al. Cutaneous and mucosal neoplasms in bone marrow transplant recipients. Cancer 1990; 65:473-6.
48. Rizzo JD, Curtis RE, Socie G et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113:1175-83.
49. Deeg HJ, Socie G, Schoch G et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87:386-92. (Pubitemid 26011854)
50. Curtis RE, Metayer C, Rizzo JD et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105:3802-11. (Pubitemid 40662691)
51. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001; 358:1042-5. (Pubitemid 32925124)
52. Guba M, Graeb C, Jauch K-W et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004; 77:1777-82. (Pubitemid 38822196)
53. Dupuy P, Bagot M, Michel L et al. Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro. J Invest Dermatol 1991; 96:408-13.
54. Borghi-Cirri MB, Riccardi-Arbi R, Bacci S et al. Inhibited differentiation of Langerhans cells in the rat epidermis upon systemic treatment with cyclosporin A. Histol Histopathol 2001; 16:107-12. (Pubitemid 32094028)
55. Sauma D, Fierro A, Mora JR et al. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect. Transplant Proc 2003; 35:2515-17. (Pubitemid 37378045)
56. Abdul M, Charron D, Haziot A. Selective effects of cyclosporine A on Th2-skewed dendritic cells matured with viral-like stimulus by means of toll-like receptors. Transplantation 2008; 86:880-4.
57. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530-4.
58. Han W, Ming M, He TC et al. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem 2010; 285:11369-77.
59. Wu X, Nguyen BC, Dziunycz P et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature 2010; 465:368-72.
60. Walsh SB, Xu J, Xu H et al. Cyclosporine A mediates pathogenesis of aggressive cutaneous squamous cell carcinoma by augmenting epithelial- mesenchymal transition: role of TGFbeta signaling pathway. Mol Carcinog 2011; 9:20744.
61. Scott LJ, McKeage K, Keam SJ et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63:1247-97. (Pubitemid 36750952)
62. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4:905-13. (Pubitemid 38745589)
63. Marcen R, Galeano C, Fernandez-Rodriguez A et al. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation. Transplant Proc 2010; 42:3055-7.
64. Marcen R, Pascual J, Tato AM et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003; 35:1714-16. (Pubitemid 37093684)
65. Bichari W, Bartiromo M, Mohey H et al. Significant risk factors for occurrence of cancer after renal transplantation: a single center cohort study of 1265 cases. Transplant Proc 2009; 41:672-3.
66. Bottomley WW, Ford G, Cunliffe WJ et al. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995; 133:460-2.
67. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309:1871-4. (Pubitemid 41325100)
68. de Graaf YG, Rebel H, Elghalbzouri A et al. More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol 2008; 17:349-55. (Pubitemid 351338679)
69. Long MD, Herfarth HH, Pipkin CA et al. Increased risk for mon-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010; 8:268-74.
70. Gallagher MP, Kelly PJ, Jardine M et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol 2010; 21:852-8.
71. Ingvar A, Smedby KE, Lindelof B et al. Immunosuppressive treatment after solid organ transplantation and risk of post-transplant cutaneous squamous cell carcinoma. Nephrol Dial Transplant 2010; 25:2764-71.
72. Molina BD, Leiro MG, Pulpon LA et al. Incidence and risk factors for nonmelanoma skin cancer after heart transplantation. Transplant Proc 2010; 42:3001-5.
73. Einollahi B, Nemati E, Lessan-Pezeshki M et al. Skin cancer after renal transplantation: results of a multicenter study in Iran. Ann Transplant 2010; 15:44-50.
74. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:1186-91. (Pubitemid 44528284)
75. Mabrouk D, Gurcan HM, Keskin DB et al. Association between cancer and immunosuppressive therapy - analysis of selected studies in pemphigus and pemphigoid. Ann Pharmacother 2010; 44:1770-6.
76. Brewer JD, Colegio OR, Phillips PK et al. Incidence of and risk factors for skin cancer after heart transplant. Arch Dermatol 2009; 145:1391-6.
77. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17:681-4.
78. Hofbauer GF, Straub G, Meyer R et al. Switching azathioprine to mycophenolate mofetil reduces skin photosensitivity in kidney transplant recipients. In: World Congress of Nephrology. Milan, Italy, 2009.
79. Klumpen HJ, Beijnen JH, Gurney H et al. Inhibitors of mTOR. Oncologist 2010; 15:1262-9.
80. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335-40. (Pubitemid 28385231)
81. Kuo CJ, Chung J, Fiorentino DF et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992; 358:70-3.
82. von Manteuffel SR, Dennis PB, Pullen N et al. The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol 1997; 17:5426-36. (Pubitemid 27357640)
83. Brunn GJ, Hudson CC, Sekulic A et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997; 277:99-101. (Pubitemid 27450655)
84. Hara K, Yonezawa K, Kozlowski MT et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997; 272:26457-63. (Pubitemid 27458864)
85. Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-89. (Pubitemid 34876546)
86. Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163-75. (Pubitemid 34876545)
87. Kim DH, Sarbassov DD, Ali SM et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient- sensitive interaction between raptor and mTOR. Mol Cell 2003; 11:895-904. (Pubitemid 36566312)
88. Zhou H, Huang S. mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 2010; 20:1-16.
89. Luan FL, Ding R, Sharma VK et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63:917-26. (Pubitemid 36315569)
90. Huber S, Bruns CJ, Schmid G et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71:771-7. (Pubitemid 46624022)
91. Kobayashi S, Kishimoto T, Kamata S et al. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lym-phangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98:726-33. (Pubitemid 46563450)
92. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87:157-63.
93. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18:446-9. (Pubitemid 39077081)
94. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17:581-9.
95. Kahan BD, Yakupoglu YK, Schoenberg L et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749-58. (Pubitemid 41443756)
96. Tessmer CS, Magalhaes LV, Keitel E et al. Conversion to sirolimus in renal transplant recipients with skin cancer. Transplantation 2006; 82:1792-3. (Pubitemid 46035669)
97. Fernandez A, Marcen R, Pascual J et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006; 38:2453-5. (Pubitemid 44693675)
98. de Fijter JW. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 2007; 22 (Suppl. 1):i23-6.
99. Garcia-Valladares I, Cuchacovich R, Espinoza LR. Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. Drug Des Devel Ther 2011; 5:41-9.
100. Tak PP, Kalden JR. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 2011; 13 (Suppl. 1):S5.
101. Webber A, Hirose R, Vincenti F. Novel strategies in immuno-suppression: issues in perspective. Transplantation 2011; 91:1057-64.
102. Esser AC, Abril A, Fayne S et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. J Am Acad Dermatol 2004; 50:S75-7. (Pubitemid 38580526)
103. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor [alpha] receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001; 45:953-6. (Pubitemid 33096643)
104. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32:2130-5. (Pubitemid 41587856)
105. Fryrear RS II, Wiggins AK, Sangueza O et al. Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy. J Am Acad Dermatol 2004; 51:1026. (Pubitemid 39593030)
106. Ly L, Czarnecki D. The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis. Br J Dermatol 2007; 157:1076-8. (Pubitemid 47583529)
107. Comte C, Guilhou JJ, Guillot B et al. Rapid onset and fatal outcome of two squamous cell carcinomas of the genitalia in a patient treated with etanercept for cutaneous psoriasis. Dermatology 2008; 217:284-5.
108. Fulchiero GJ Jr, Salvaggio H, Drabick JJ et al. Eruptive latent meta-static melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007; 56:S65-7. (Pubitemid 46552081)
109. Becher B, Blain M, Giacomini PS et al. Inhibition of Th1 polarization by soluble TNF receptor is dependent on antigen-presenting cell-derived IL-12. J Immunol 1999; 162:684-8. (Pubitemid 29035387)
110. Smith KJ, Skelton H. Reply. J Am Acad Dermatol 2003; 49:359.
111. Dommasch ED, Abuabara K, Shin DB et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 2011; 64:1035-50.
112. Karagas MR, Cushing GL Jr, Greenberg ER et al. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85:683-6. (Pubitemid 32929465)
113. Jensen AO, Thomsen HF, Engebjerg MC et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009; 100:200-5.
114. Sorensen HT, Mellemkjaer L, Nielsen GL et al. Skin cancers and non-Hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96:709-11. (Pubitemid 38660234)
115. Buchbinder R, Barber M, Heuzenroeder L et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 2008; 59:794-9. (Pubitemid 351847561)
116. Strauss DC, Thomas JM. Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010; 11:790-6.
117. Zwald FO, Christenson LJ, Billingsley EM et al. Melanoma in solid organ transplant recipients. Am J Transplant 2010; 10:1297-304.
118. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61:274-8. (Pubitemid 26044543)
119. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003; 348:567-8. (Pubitemid 36159900)
120. Kim JK, Carmody IC, Cohen AJ et al. Donor transmission of malignant melanoma to a liver graft recipient: case report and literature review. Clin Transplant 2009; 23:571-4.
121. Morris-Stiff G, Steel A, Savage P et al. Transmission of donor melanoma to multiple organ transplant recipients. Am J Transplant 2004; 4:444-6. (Pubitemid 38282303)
122. Otley CC, Coldiron BM, Stasko T et al. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppres-sants. Arch Dermatol 2001; 137:459-63. (Pubitemid 32319841)
123. Kutting B, Drexler H. UV-induced skin cancer at workplace and evidence-based prevention. Int Arch Occup Environ Health 2010; 83:843-54.
124. Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst 1974; 53:1333-6.
125. Kripke ML. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 1977; 37:1395-400. (Pubitemid 8104878)
126. Fisher MS, Kripke ML. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 1982; 216:1133-4. (Pubitemid 12063276)
127. Moodycliffe AM, Nghiem D, Clydesdale G et al. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1:521-5.
128. Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells - from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol 2008; 84:10-18. (Pubitemid 350265098)
129. de Gruijl FR. UV-induced immunosuppression in the balance. Photochem Photobiol 2008; 84:2-9. (Pubitemid 350284491)
130. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res 2005; 571:185-205. (Pubitemid 40313441)
131. Cestari TF, Kripke ML, Baptista PL et al. Ultraviolet radiation decreases the granulomatous response to lepromin in humans. J Invest Dermatol 1995; 105:8-13.
132. Damian DL, Halliday GM, Taylor CA et al. Ultraviolet radiation induced suppression of Mantoux reactions in humans. J Invest Dermatol 1998; 110:824-7. (Pubitemid 28194035)
133. Moyal D. Immunosuppression induced by chronic ultraviolet irradiation in humans and its prevention by sunscreens. Eur J Dermatol 1998; 8:209-11. (Pubitemid 28218608)
134. Cooper KD, Oberhelman L, Hamilton TA et al. UV exposure reduces immunization rates and promotes tolerance to epicutane-ous antigens in humans: relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion. Proc Natl Acad Sci USA 1992; 89:8497-501.
135. Damian DL, Halliday GM, Barnetson RS. Broad-spectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppression of contact hypersensitivity to a recall antigen in humans. J Invest Dermatol 1997; 109:146-51. (Pubitemid 27337327)
136. Kelly DA, Seed PT, Young AR et al. A commercial sunscreen's protection against ultraviolet radiation-induced immunosuppression is more than 50% lower than protection against sunburn in humans. J Invest Dermatol 2003; 120:65-71. (Pubitemid 36120972)
137. Matthews YJ, Halliday GM, Phan TA et al. Wavelength dependency for UVA-induced suppression of recall immunity in humans. J Dermatol Sci 2010; 59:192-7.
138. Kelly DA, Walker SL, McGregor JM et al. A single exposure of solar simulated radiation suppresses contact hypersensitivity responses both locally and systemically in humans: quantitative studies with high-frequency ultrasound. J Photochem Photobiol B 1998; 44:130-42. (Pubitemid 28505177)
139. Norval M. Effects of solar radiation on the human immune system. J Photochem Photobiol B 2001; 63:28-40. (Pubitemid 33040720)
140. O'Dell BL, Jessen RT, Becker LE et al. Diminished immune response in sun-damaged skin. Arch Dermatol 1980; 116:559-61. (Pubitemid 10101711)
141. Yoshikawa T, Rae V, Bruins-Slot W et al. Susceptibility to effects of UVB radiation on induction of contact hypersensitiv-ity as a risk factor for skin cancer in humans. J Invest Dermatol 1990; 95:530-6.
142. Damian DL, Patterson CR, Stapelberg M et al. UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol 2008; 128:447-54.
143. Schwarz A, Noordegraaf M, Maeda A et al. Langerhans cells are required for UVR-induced immunosuppression. J Invest Dermatol 2010; 130:1419-27.
144. Loser K, Beissert S. Regulation of cutaneous immunity by the environment: an important role for UV irradiation and vitamin D. Int Immunopharmacol 2009; 9:587-9.
145. Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur J Dermatol 2003; 13:515-23. (Pubitemid 38030789)
146. Stege H, Roza L, Vink AA et al. Enzyme plus light therapy to repair DNA damage in ultraviolet-B-irradiated human skin. Proc Natl Acad Sci USA 2000; 97:1790-5. (Pubitemid 30118521)
147. Sreevidya CS, Fukunaga A, Khaskhely NM et al. Agents that reverse UV-induced immune suppression and photocarcinogenesis affect DNA repair. J Invest Dermatol 2010; 130:1428-37.
148. Walterscheid JP, Ullrich SE, Nghiem DX. Platelet-activating factor, a molecular sensor for cellular damage, activates systemic immune suppression. J Exp Med 2002; 195:171-9. (Pubitemid 34461261)
149. Nindl I, Rosl F. Molecular concepts of virus infections causing skin cancer in organ transplant recipients. Am J Transplant 2008; 8:2199-204.
150. Dubina M, Goldenberg G. Viral-associated nonmelanoma skin cancers: a review. Am J Dermatopathol 2009; 31:561-73.
151. Moy RL, Eliezri YD, Nuovo GJ et al. Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. JAMA 1989; 261:2669-73. (Pubitemid 19127962)
152. Mendez JC, Procop GW, Espy MJ et al. Relationship of HHV8 replication and Kaposi's sarcoma after solid organ transplantation. Transplantation 1999; 67:1200-1. (Pubitemid 29205589)
153. Hsu JY, Chen AC, Keleher A et al. Shared and persistent asymptomatic cutaneous human papillomavirus infections in healthy skin. J Med Virol 2009; 81:1444-9.
154. Bouvard V, Baan R, Straif K et al. A review of human carcinogens - part B: biological agents. Lancet Oncol 2009; 10:321-2.
155. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26:1657-67. (Pubitemid 41487981)
156. Tuttleton Arron S, Jennings L, Nindl I et al. Viral oncogenesis and its role in nonmelanoma skin cancer. Br J Dermatol 2011; 164:1201-13.
157. Arron ST, Ruby JG, Dybbro E et al. Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131:1745-53.
158. Weissenborn SJ, Nindl I, Purdie K et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol 2005; 125:93-7. (Pubitemid 40981429)
159. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19:592-8. (Pubitemid 30099373)
160. Jackson S, Harwood C, Thomas M et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev 2000; 14:3065-73.
161. Iftner T, Elbel M, Schopp B et al. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO J 2002; 21:4741-8. (Pubitemid 34984361)
162. Feng H, Shuda M, Chang Y et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319:1096-100. (Pubitemid 351300792)
163. Koljonen V, Kukko H, Tukiainen E et al. Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant 2009; 24:3231-5.
164. Kassem A, Technau K, Kurz AK et al. Merkel cell polyomavirus sequences are frequently detected in nonmelanoma skin cancer of immunosuppressed patients. Int J Cancer 2009; 125:356-61.
165. Wieland U, Mauch C, Kreuter A et al. Merkel cell polyomavirus DNA in persons without Merkel cell carcinoma. Emerg Infect Dis 2009; 15:1496-8.
166. Foulongne V, Dereure O, Kluger N et al. Merkel cell polyomavirus DNA detection in lesional and nonlesional skin from patients with Merkel cell carcinoma or other skin diseases. Br J Dermatol 2010; 162:59-63.
167. Dworkin AM, Tseng SY, Allain DC et al. Merkel cell polyomavirus in cutaneous squamous cell carcinoma of immunocompetent individuals. J Invest Dermatol 2009; 129:2868-74.
168. Shuda M, Arora R, Kwun HJ et al. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer 2009; 125:1243-9.
169. Shuda M, Feng H, Kwun HJ et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008; 105:16272-7.
170. Houben R, Shuda M, Weinkam R et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010; 84:7064-72.
171. Touze A, Le Bidre E, Laude H et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol 2011; 29:1612-19.
172. Mocellin S, Pasquali S, Rossi CR et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493-501.
173. Tsai KY. Systemic adjuvant therapy for patients with high-risk melanoma. Arch Dermatol 2007; 143:779-82. (Pubitemid 46955739)
174. Hershkovitz L, Schachter J, Treves AJ, Besser MJ. Focus on adoptive T cell transfer trials in melanoma. Clin Dev Immunol 2010; 2010:260267.
175. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314:126-9. (Pubitemid 44547756)
176. Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009; 114:535-46.
177. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9.
178. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23.
179. Tivol EA, Borriello F, Schweitzer AN et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7.
180. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270:985-8.
181. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13.
182. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci USA 1998; 95:10067-71. (Pubitemid 28415295)
183. Hurwitz AA, Foster BA, Kwon ED et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-8. (Pubitemid 30262435)
184. van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66. (Pubitemid 29374833)
185. Kwon ED, Foster BA, Hurwitz AA et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96:15074-9. (Pubitemid 30019767)
186. Mokyr MB, Kalinichenko T, Gorelik L et al. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 1998; 58:5301-4. (Pubitemid 28551104)
187. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100:4712-17. (Pubitemid 36457795)
188. Liakou CI, Kamat A, Tang DN et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA 2008; 105:14987-92.
189. Hoos A, Ibrahim R, Korman A et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37:533-46.
190. Wagstaff AJ, Perry CM. Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions. Drugs 2007; 67:2187-210. (Pubitemid 47557094)
191. Imiquimod for superficial and in situ skin malignancy. Drug Ther Bull 2009; 47:113-16.
192. Torres A, Storey L, Anders M et al. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 2007; 5:7.
193. Wenzel J, Uerlich M, Haller O et al. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod. J Cutan Pathol 2005; 32:257-62. (Pubitemid 40459926)
194. Wolf IH, Kodama K, Cerroni L et al. Nature of inflammatory infiltrate in superficial cutaneous malignancies during topical imiquimod treatment. Am J Dermatopathol 2007; 29:237-41. (Pubitemid 46801921)
195. Huang SJ, Hijnen D, Murphy GF et al. Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol 2009; 129:2676-85.
196. De Giorgi V, Salvini C, Chiarugi A et al. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int J Dermatol 2009; 48:312-21.
197. Schon MP, Schon M, Klotz KN. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol 2006; 126:1338-47. (Pubitemid 43997917)
198. Clark RA, Huang SJ, Murphy GF et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008; 205:2221-34.
199. Micali G, Lacarrubba F, Dinotta F et al. Treating skin cancer with topical cream. Expert Opin Pharmacother 2010; 11:1515-27.
200. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145:1431-8.
201. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007; 1:CD003412.
202. Kim KH, Yavel RM, Gross VL et al. Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited. Dermatol Surg 2004; 30:116-20. (Pubitemid 38174043)
203. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2011; 64:413-22.
204. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357:539-45. (Pubitemid 32173595)
205. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008; 9:628-38.
206. Kerr-Valentic MA, Samimi K, Rohlen BH et al. Marjolin's ulcer: modern analysis of an ancient problem. Plast Reconstr Surg 2009; 123:184-91.
207. Baldursson B, Sigurgeirsson B, Lindelof B. Leg ulcers and squamous cell carcinoma. An epidemiological study and a review of the literature. Acta Derm Venereol (Stockh) 1993; 73:171-4. (Pubitemid 23214187)
208. Baldursson BT, Hedblad MA, Beitner H et al. Squamous cell carcinoma complicating chronic venous leg ulceration: a study of the histopathology, course and survival in 25 patients. Br J Dermatol 1999; 140:1148-52. (Pubitemid 29284593)
209. Asuquo M, Ugare G, Ebughe G et al. Marjolin's ulcer: the importance of surgical management of chronic cutaneous ulcers. Int J Dermatol 2007; 46 (Suppl. 2):29-32. (Pubitemid 350066593)
210. Richardus JH, Smith TC. Squamous cell carcinoma in chronic ulcers in leprosy: a review of 38 consecutive cases. Lepr Rev 1991; 62:381-8.
211. Eroglu A, Camlibel S. Risk factors for locoregional recurrence of scar carcinoma. Br J Surg 1997; 84:1744-6. (Pubitemid 27519611)
212. Mullen JT, Feng L, Xing Y et al. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol 2006; 13:902-9.
213. Lindelof B, Krynitz B, Granath F et al. Burn injuries and skin cancer: a population-based cohort study. Acta Derm Venereol (Stockh) 2008; 88:20-2. (Pubitemid 351212129)
214. Mellemkjaer L, Holmich LR, Gridley G et al. Risks for skin and other cancers up to 25 years after burn injuries. Epidemiology 2006; 17:668-73. (Pubitemid 44655603)
215. Mantovani A, Allavena P, Sica A et al. Cancer-related inflammation. Nature 2008; 454:436-44.
216. Nickoloff BJ, Ben-Neriah Y, Pikarsky E. Inflammation and cancer: is the link as simple as we think? J Invest Dermatol 2005; 124:x-xiv. (Pubitemid 40847392)
217. Haeffner AC, Zepter K, Elmets CA et al. Analysis of tumor-infiltrating lymphocytes in cutaneous squamous cell carcinoma. Arch Der-matol 1997; 133:585-90. (Pubitemid 27214967)
218. Harwood CA, Proby CM, McGregor JM et al. Clinicopathologic features of skin cancer in organ transplant recipients: a retrospective case-control series. J Am Acad Dermatol 2006; 54:290-300. (Pubitemid 43144399)
219. Muhleisen B, Petrov I, Gachter T et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology 2009; 55:67-76.
220. Filaci G, Fenoglio D, Fravega M et al. CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179:4323-34.
221. Ghiringhelli F, Menard C, Terme M et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202:1075-85. (Pubitemid 41464501)
222. Chen ML, Pittet MJ, Gorelik L et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 2005; 102: 419-24. (Pubitemid 40116782)
223. Sakaguchi S, Wing K, Onishi Y et al. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21: 1105-11.
224. Bates GJ, Fox SB, Han C et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006; 24: 5373-80. (Pubitemid 46623168)
225. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9. (Pubitemid 39273735)
226. Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcino-genesis. Clin Cancer Res 2007; 13:902-11. (Pubitemid 46340366)
227. Hiraoka N, Onozato K, Kosuge T et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006; 12:5423-34. (Pubitemid 44497257)
228. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102:18538-43. (Pubitemid 43011261)
229. Kaporis HG, Guttman-Yassky E, Lowes MA et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol 2007; 127:2391-8. (Pubitemid 47619759)
230. Schwarz S, Butz M, Morsczeck C et al. Increased number of CD25 FoxP3 regulatory T cells in oral squamous cell carcinomas detected by chromogenic immunohistochemical double staining. J Oral Pathol Med 2008; 37:485-9.
231. Mourmouras V, Fimiani M, Rubegni P et al. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol 2007; 157:531-9. (Pubitemid 47256132)
232. Viguier M, Lemaitre F, Verola O et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-53. (Pubitemid 38924326)
233. Ahmadzadeh M, Felipe-Silva A, Heemskerk B et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112:4953-60.
234. O'Garra A, Barrat FJ. In vitro generation of IL-10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by Th1- and Th2-inducing cytokines. Immunol Lett 2003; 85:135-9. (Pubitemid 36071567)
235. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-8.
236. Jang TJ. Prevalence of Foxp3 positive T regulatory cells is increased during progression of cutaneous squamous tumors. Yonsei Med J 2008; 49:942-8.
237. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21:713-22.
238. Kosmidis M, Dziunycz P, Suárez-Fariñas M et al. Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J Immunother 2010; 33:538-46.
239. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002; 23:445-9. (Pubitemid 35015188)
240. Bluth MJ, Zaba LC, Moussai D et al. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Invest Dermatol 2009; 129:2451-62.
241. Charles J, Chaperot L, Salameire D et al. Plasmacytoid dendritic cells and dermatological disorders: focus on their role in autoimmunity and cancer. Eur J Dermatol 2010; 20:16-23.
242. Urosevic M, Dummer R, Conrad C et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97:1143-53. (Pubitemid 41511214)
243. Tjiu JW, Chen JS, Shun CT et al. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol 2009; 129:1016-25.
244. Pettersen JS, Fuentes-Duculan J, Suárez-Fariñas M et al. Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol 2011; 131:1322-30.
245. Moussai D, Mitsui H, Pettersen JS et al. The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macro-phage-derived VEGF-C. J Invest Dermatol 2011; 131:229-36.
246. Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296:2823-31. (Pubitemid 44969182)
247. Le Mire L, Hollowood K, Gray D et al. Melanomas in renal transplant recipients. Br J Dermatol 2006; 154:472-7. (Pubitemid 43382655)
248. Hollenbeak CS, Todd MM, Billingsley EM et al. Increased incidence of melanoma in renal transplantation recipients. Cancer 2005; 104:1962-7. (Pubitemid 41513181)